Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity

Journal of Immunology

Volumn 182, Issue 7, 2009, Pages 4217-4225

  Kilinc, Mehmet O ^a   Gu, Tao ^a   Harden, Jamie L ^a   Virtuoso, Lauren P ^a   Egilmez, Nejat K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LYMPHOCYTE ANTIBODY; PERFORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; KNOCKOUT MOUSE; MALE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CYTOLOGY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE ACTIVATION; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHEMOTAXIS, LEUKOCYTE; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOLOGIC MEMORY; INTERLEUKIN-12; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL;

EID: 64249096161     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802793     Document Type: Article

References (34)

1. Guinn, B.-A., N. Kasahara, F. Farzaneh, N. A. Habib, J. S. Norris, and A. B. Deisseroth. 2007. Recent advances and current challenges in tumor immunology and immunotherapy. Mol. Therapy 15: 1065-1071.
2. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915. (Pubitemid 39273730)
3. Gajewski, T. F. 2007. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13: 5256-5261.
4. Mantovani, A., P. Romero, A. K. Palucka, and F. M. Marincola. 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
5. + T cells in patients with melanoma. J. Immunol. 175: 6169-6176.
6. + T cells following tumor infiltration. Cancer Res. 68: 2993-3000.
7. Frey, A. B., and N. Monu. 2008. Signaling defects in anti-tumor T cells. Immunol. Rev. 222: 192-205.
8. Simpson-Abelson, M., and R. B. Bankert. 2008. Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment. Expert Opin. Ther. Targets 12: 477-490. (Pubitemid 351546372)
9. Luscher, U., L. Filgueira, A. Juretic, M. Zuber, N. J. Luscher, M. Heberer, and G. C. Spagnoli. 1994. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer 57: 612-619. (Pubitemid 24173111)
10. + tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 167: 5042-5051.
11. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
12. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
13. Zang, X., and J. P. Allison. 2007. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 13: 5271-5279. (Pubitemid 47510350)
14. Webster, W. H., R. H. Thompson, K. J. Harris, S. Frigola, S. Kuntz, B. A. Inman, and H. Dong. 2007. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 79: 2860-2869.
15. Egilmez, N. K., Y. S. Jong, M. S. Sabel, J. S. Jacob, E. Mathiowitz, and R. B. Bankert. 2000. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60: 3832-3837.
16. + T cells. Cancer Res. 68: 2972-2983.
17. Currie, A. J., R. G. van der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. S. Robinson. 2008. Targeting the effector site with IFN-αβ-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J. Immunol. 180: 1535-1544.
18. + T effectors. J. Immunol. 177: 6962-6973.
19. Hill, H. C., T. F. Conway, Jr., M. S. Sabel, Y. S. Jong, E. Mathiowitz, R. B. Bankert, and N. K. Egilmez. 2002. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62: 7254-7263.
20. Blieden, T. M., A. J. McAdam, J. G. Frelinger, and E. M. Lord. 1991. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J. Immunol. 147: 1433-1438.
21. Nair, R. E., J. S. Jong, S. A. Jones, A. Sharma, E. Mathiowitz, and N. K. Egilmez. 2006. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J. Immunother. 29: 10-20. (Pubitemid 43756077)
22. Gu, T., M. O. Kilinc, and N. K. Egilmez. 2008. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. Cancer Immunol. Immunother. 57: 997-1005.
23. + T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157: 978-983.
24. Storni, T., and M. Bachmann 2003. On the role of APC-activation for in vitro versus in vivo T cell priming. Cell. Immunol. 225: 1-11. (Pubitemid 37468457)
25. Masopust, D., and R. Ahmed. 2004. Reflections on CD8 T-cell activation and memory. Immunol. Res. 29: 151-160.
26. Iwasaki, M., T. Mukai, P. Gao, W.-R. Park, C. Nakajima, M. Tomura, H. Fujiwara, and T. Hamaoka. 2001. A critical role for IL-12 in CCR5 induction on T cell receptor-triggered mouse CD4+ and CD8+ T cells. Eur. J. Immunol. 31: 2411-2420. (Pubitemid 33144180)
27. Watkins, S. K., N. K. Egilmez, J. Suttles, and R. D. Stout. 2007. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 178: 1357-1362.
28. + T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J. Immunol. 170: 400-412.
29. Colombo, M. P., and G. Trinchieri. 2002. Mini review: interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 155-168.
30. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15: 749-795.
31. Glimcher, L. H., M. J. Townsend, B. M. Sullivan, and G. M. Lord. 2004. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4: 900-911.
32. + T cells after infection. Nat. Immunol. 3: 619-626.
33. Mescher, M. F., F. E. Popescu, M. Gerner, C. D. Hammerbeck, and J. M. Curtsinger. 2007. Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin. Cancer Biol. 17: 299-308.
34. + T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J. Immunol. 176: 7325-7334.